Everything old is new again: drug repurposing approach for non-small cell lung cancer targeting MAPK signaling pathway
Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …
for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85 …
Cancer metabolism as a therapeutic target and review of interventions
Cancer is amenable to low-cost treatments, given that it has a significant metabolic
component, which can be affected through diet and lifestyle change at minimal cost. The …
component, which can be affected through diet and lifestyle change at minimal cost. The …
[HTML][HTML] A minimalist and robust chemo-photothermal nanoplatform capable of augmenting autophagy-modulated immune response against breast cancer
Previously used in anti-fungal therapy, itraconazole has now been shown to be successful in
treating advanced breast cancer (NCT00798135). However, its poor solubility still restricts its …
treating advanced breast cancer (NCT00798135). However, its poor solubility still restricts its …
[HTML][HTML] Itraconazole inhibits endothelial cell migration by disrupting inositol pyrophosphate-dependent focal adhesion dynamics and cytoskeletal remodeling
J Qi, W Cheng, Z Gao, Y Chen, ML Shipton… - Biomedicine & …, 2023 - Elsevier
The antifungal drug itraconazole has been repurposed to anti-angiogenic agent, but the
mechanisms of action have been elusive. Here we report that itraconazole disrupts focal …
mechanisms of action have been elusive. Here we report that itraconazole disrupts focal …
First-line gemcitabine, nab-paclitaxel, and oxaliplatin chemotherapy with itraconazole in patients with metastatic pancreatic cancer: a single institution experience
M Sawasaki, H Tsubamoto, A Sugihara… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Combination chemotherapy with gemcitabine, nab-paclitaxel, oxaliplatin,
and itraconazole (GnPO-ITC) was administered as first-line chemotherapy in patients with …
and itraconazole (GnPO-ITC) was administered as first-line chemotherapy in patients with …
Mdact: A new principle of adjunctive cancer treatment using combinations of multiple repurposed drugs, with an example regimen
Simple Summary We present eight core attributes of cancer growth that we must address for
a more effective treatment than we currently have. To do this we outline why a regimen …
a more effective treatment than we currently have. To do this we outline why a regimen …
Itraconazole exerts its antitumor effect in esophageal cancer by suppressing the HER2/AKT signaling pathway
W Zhang, AS Bhagwath, Z Ramzan, TA Williams… - Molecular cancer …, 2021 - AACR
Itraconazole, an FDA-approved antifungal, has antitumor activity against a variety of
cancers. We sought to determine the effects of itraconazole on esophageal cancer and …
cancers. We sought to determine the effects of itraconazole on esophageal cancer and …
Unlocking the potential of signature-based drug repurposing for anticancer drug discovery
S Biswal, B Mallick - Archives of Biochemistry and Biophysics, 2024 - Elsevier
Cancer is the leading cause of death worldwide and is often associated with tumor relapse
even after chemotherapeutics. This reveals malignancy is a complex process, and high …
even after chemotherapeutics. This reveals malignancy is a complex process, and high …
Synthesis, in silico studies and in vitro cytotoxicity evaluation of novel posaconazole derivative as a ALK TK inhibitor
Oncology research progresses, yet cancer remains the largest medical need. The use of a
medication with an accessible lead molecule shows great potential for long-term cancer …
medication with an accessible lead molecule shows great potential for long-term cancer …
The effect of itraconazole on the clinical outcomes of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a randomized …
AW Mohamed, M Elbassiouny, DA Elkhodary… - Medical Oncology, 2021 - Springer
Itraconazole is an oral antifungal that has a been reported to have anticancer effect in non-
small cell lung cancer (NSCLC) through inhibition of angiogenesis. The aim is to evaluate …
small cell lung cancer (NSCLC) through inhibition of angiogenesis. The aim is to evaluate …